One biotechnology and drugs player that insiders are loading up on here is
(ACRX - Get Report)
. This company develops and commercializes therapies for the treatment of pain. Insiders are buying this stock into extreme strength, since shares are up over 80% so far in 2012.
AcelRx Pharmaceuticals has a market cap of $79 million and an enterprise value of $72 million. This stock trades at a premium valuation, with a price-to-sales of 58.34. Its estimated growth rate for this year is -31%, and for next year it's pegged 41.4%. This is barely a cash-rich company, since the total cash position on its balance sheet is $23.38 million and its total debt is $17.68 million.
A beneficial owner and director just
bought 2,416,918 shares, or $7.99 million worth of stock, at $3.31 per share.
From a technical perspective, ACRX is currently trending above both its 50-day and 200-day moving averages, which is bullish. This stock recently sold off sharply from its November high of $5.25 to its recent low of $3.30 a share. During that selloff, shares of ACRX were consistently making lower highs and lower lows, which is bearish technical price action. That said, if ACRX can hold that $3.30 low then the stock could be setting up to rebound again and breakout.
If you're bullish on ACRX, then I would look for long-biased trades once this stock manages to break out above some near-term overhead resistance at $3.71 a share with high volume. Look for a sustained move or close above $3.71 a share with volume that registers near or above its three-month average action of 206,758 shares. If that breakout triggers soon, then ACRX will set up to re-test or possibly take out its next major overhead resistance levels at $4.80 to $5.25 a share.
Another name in the semiconductor complex that insiders are snapping up a large amount of stock in is
. This company designs, develops and markets high-performance, cost-competitive semiconductor solutions for Carrier and Enterprise networks worldwide. Insiders are buying this stock into weakness, since shares are down by 26% so far in 2012.